Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [4][8]. Core Viewpoints - The report continues to recommend the innovative pharmaceutical and medical device industry chain, highlighting a selection of A-share and H-share stocks with an "Overweight" rating [2][8][11]. - The performance of the pharmaceutical sector in December 2025 was weaker than the broader market, with the SW Pharmaceutical Biotechnology index declining by 4.1% compared to a 2.1% increase in the Shanghai Composite Index [18][30]. - The report notes that the premium level of the pharmaceutical sector relative to the entire A-share market is currently at a normal level, with a relative premium rate of 63.2% as of December 31, 2025 [29][32]. Summary by Sections A-Share Recommendations - The report lists the following A-share stocks with an "Overweight" rating: - 恒瑞医药 (Hengrui Medicine) - 科伦药业 (Kelun Pharmaceutical) - 华东医药 (East China Pharmaceutical) - 恩华药业 (Enhua Pharmaceutical) - 特宝生物 (Tebao Biological) - 京新药业 (Jingxin Pharmaceutical) - 益方生物 (Yifang Biological) - 药明康德 (WuXi AppTec) - 泰格医药 (Tigermed) - 乐普医疗 (Lepu Medical) - 联影医疗 (United Imaging) - 微电生理 (Microelectrophysiology) [8][9]. H-Share Recommendations - The report maintains an "Overweight" rating for the following H-share stocks: - 翰森制药 (Hansoh Pharmaceutical) - 三生制药 (3SBio) - 科伦博泰生物 (Kelun-Botai Biological) - 康方生物 (CanSino Biologics) - 映恩生物 (InnoCare Pharma) - 百济神州 (BeiGene) [11][12]. Performance Analysis - The report indicates that the 国泰海通医药 monthly portfolio outperformed the pharmaceutical index in December 2025, with an average decline of 1.8% compared to a 3.9% decline in the overall pharmaceutical index [14][15]. - The report highlights the best-performing stocks in December 2025, with 泰格医药 (Tigermed) increasing by 11.2%, 特宝生物 (Tebao Biological) by 7.5%, and 惠泰医疗 (Huitai Medical) by 3.9% [15][18].

Core Insights - The number of headquarters enterprises in Sichuan has expanded, with 31 companies recognized, bringing the total to 128 [1] - Headquarters enterprises are defined as those registered in Sichuan that conduct cross-regional operations and contribute significantly to local taxes and the economy [1] Group 1: Enterprise Distribution - The newly recognized 31 enterprises are primarily located in six cities, with a majority being private enterprises (48.4%), followed by state-owned enterprises (41.9%), foreign enterprises (6.5%), and mixed-ownership enterprises (3.2%) [2] - The main sectors represented are manufacturing (51.6%), services (32.3%), and construction (9.7%), aligning with Sichuan's modern industrial development [2] - Among these enterprises, seven have annual revenues exceeding 10 billion, and one exceeds 100 billion [2] Group 2: Classification of Headquarters - Sichuan classifies headquarters enterprises into three categories: comprehensive headquarters, functional headquarters, and growth headquarters [2] - Comprehensive headquarters must meet large enterprise standards in terms of revenue, total assets, and workforce [2] - Five functional headquarters are controlled by large enterprises from outside the province or abroad, requiring a minimum registered capital of 50 million [2] Group 3: Support Policies - Sichuan will utilize various policy tools, including fiscal, financial, technological, and talent support, to promote the development of headquarters enterprises [3] - There is an emphasis on policy coordination across provincial, municipal, and county levels to enhance the effectiveness of support measures [3]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.05% on December 31, reaching 29.42 yuan per share, and a total market capitalization of 47.015 billion yuan [1] - As of September 30, 2025, Kelun Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company has a diverse revenue structure, with 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - Kelun Pharmaceutical has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] - The number of shareholders increased to 37,100 as of September 30, 2025, reflecting an 8.35% rise, while the average number of circulating shares per person decreased by 7.70% to 35,200 shares [2] - Major shareholders include China Europe Medical Health Mixed A, holding 40.0624 million shares, and Hong Kong Central Clearing Limited, holding 34.728 million shares, both of which have seen a reduction in their holdings compared to the previous period [3]

园区赛事激发基层活力。通过示范引领、经费补助、联合办赛等方式，新都区持续激发基层办赛 积极性。联动新都高新区在2025年开展劳动和技能竞赛5场，覆盖80余家重点产业链企业。 重点企业积极参与岗位练兵。中国航发成都发动机有限公司（简称中国航发成发）、四川科伦药 业股份有限公司（简称科伦药业）、成都正恒动力股份有限公司（简称正恒动力）、中粮可口可 乐饮料（四川）有限公司（简称中粮可口可乐四川公司）、航空工业泛华等重点企业开展岗位练 兵和技能比武超过40场，参与班组超200个，参与职工达1.1万人次，打通了成都百万职工技能大 赛至生产一线的"最后一公里"。 □新工号 2025年5月22—23日，2025年成都百万职工技能大赛新都区数控铣工、焊工技能比赛在成都市现代 制造职业技术学校举行，来自四川成都新都高新技术产业园区（简称新都高新区）的近100名高技 能职工选手展开对决。 "技能比赛为我们提供了很好的平台，我从中级工晋升到高级工，还获得成都工匠称号。"四川泛 华航空仪表电器有限公司（简称航空工业泛华）的数控车工龙涛说。他曾在2024年成都百万职工 技能大赛数控车工技能比赛中获得冠军。 一组组扎实数据、一个个鲜活案 ...

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Core Insights - 2025 marks a pivotal year for China's innovative pharmaceuticals, with a significant increase in international collaborations and licensing agreements, indicating a shift from a pharmaceutical giant to a stronghold in the industry [1][3] - The total amount of outbound licensing agreements exceeded $100 billion, with upfront payments reaching $8.1 billion, showcasing a transition to multi-layered cooperation models [1][3] - China's biopharmaceutical market remains the second largest globally, with innovative drugs accounting for approximately 30% of global research, reflecting a critical leap from following to competing on a global scale [1][3] Internationalization - The internationalization of China's pharmaceutical industry saw explosive growth in 2025, highlighted by a surge in business development (BD) transactions and the popularity of "A+H" listings [3][4] - The total amount of outbound licensing for innovative drugs reached over $100 billion, a 75% increase from 2024, indicating a shift from merely selling products to actively engaging in global markets [3][4] - Notable BD transactions include significant agreements between major Chinese pharmaceutical companies and international firms, such as a $12.5 billion deal between Hengrui Medicine and GSK [3][4] Innovation - In 2025, advancements in cutting-edge technologies such as antibody-drug conjugates (ADC) and dual antibodies have shown promising results in cancer treatment [7][8] - The third-generation ADC technology has become mainstream, with significant efficacy demonstrated in treating solid tumors [7] - The dual antibody sector continues to lead, with Chinese companies achieving remarkable results in clinical trials, such as a 91% improvement in progression-free survival compared to existing treatments [8] Policy Support - The policy support for innovative drugs in China has reached unprecedented levels, with a notable increase in the number of approved innovative drugs [10][11] - The National Medical Products Administration approved 69 innovative drugs in 2025, a 44% increase from the previous year, covering various therapeutic areas [10] - The payment system for innovative drugs has been significantly upgraded, enhancing accessibility and affordability for patients [10][11] Mergers and Acquisitions - The pharmaceutical sector has seen a surge in mergers and acquisitions, with over 400 transactions announced globally, totaling approximately $111 billion, marking a 50% increase from 2024 [13][14] - Domestic mergers also showed strong activity, with significant deals indicating a shift towards quality improvement and resource consolidation among leading companies [13][14] - The trend reflects a transition from scale expansion to enhancing quality and efficiency, with companies focusing on high-value clinical pipelines [14]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The number of innovative drugs listed in China continues to grow, with domestic products accounting for approximately half of the total market share. The R&D capabilities for innovative drugs in China are also increasing, attracting global attention. Notably, the number and value of domestic innovative drug business development (BD) transactions have reached new highs, with ADC, bispecific antibodies, small nucleic acids, and CAR-T being the four key R&D directions to watch in 2026 [15][21][22] - The Chinese innovative drug market has seen a significant increase in the number of new drug applications (NDA), with domestic products making up a growing proportion. From 2017 to 2024, the number of innovative drugs listed in China rose from 41 to 92, with domestic products accounting for 50% of the total by 2024 [17][21] - The report highlights that the license-out transaction volume and total amount for Chinese companies reached $92.03 billion in the first three quarters of 2025, a 77% increase compared to the total for 2024. The upfront payment for license-out transactions has also surpassed the total financing amount in the primary market for the same period [22][25] Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a year-to-date increase of 14.29%, while the Hang Seng Healthcare Index has surged by 62.29% [3][8] - The report notes that the pharmaceutical sector has experienced fluctuations, with raw materials and medical devices showing positive growth [8] R&D Progress and Company Dynamics - The report provides an overview of the R&D progress for innovative and modified drugs, including approvals and clinical applications [5] - It lists key companies to watch in various sub-sectors, including innovative drugs, research services, and medical devices, with specific recommendations for companies like Innovent Biologics, Hengrui Medicine, and WuXi AppTec [11][12] Market Insights and Regulatory Observations - The report tracks the price-to-earnings ratio of the pharmaceutical index, noting that it is currently lower than historical averages [5] - It emphasizes the importance of the regulatory environment and market dynamics in shaping the future of the pharmaceutical industry [5]

Core Viewpoint - Kelong Pharmaceutical's stock has experienced a decline, with a current price of 29.87 yuan per share and a market capitalization of 47.734 billion yuan, reflecting a challenging financial performance in recent months [1] Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company's stock price has increased by 1.93% year-to-date, but has seen declines of 5.74% over the last five trading days, 13.22% over the last 20 days, and 20.27% over the last 60 days [1] Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period, with an average of 35,200 circulating shares per shareholder, a decrease of 7.70% [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, notable changes include a decrease in holdings by major funds such as China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]

2025年1至6月份，科伦药业的营业收入构成为：医药制造业占比89.66%，研发项目占比7.01%，其他业 务占比3.33%。 截至发稿，科伦药业市值为490亿元。 每经AI快讯，科伦药业（SZ 002422，收盘价：30.66元）12月24日晚间发布公告称，公司第八届第十次 董事会会议于2025年12月23日以通讯的方式召开。会议审议了《关于预计公司2026年度部分日常关联交 易情况的议案》等文件。 每经头条（nbdtoutiao）——左手"欠款"右手"豪购"！杨陵江收购"国内酒庄第一股"，1919是否重启上 市？"吹太多牛都实现了，但千亿还没实现，我很着急" （记者 曾健辉） ...

四川科伦药业股份有限公司 第二条 本制度适用于公司董事和高级管理人员。 第三条 公司董事、高级管理人员薪酬遵循以下原则： （一）收入水平与公司规模、经营目标与业绩匹配； （二）责、权、利对等，薪酬与岗位价值高低、履行责任义务大小相符； （三）与公司长远利益、持续健康发展的目标相符； （四）激励与约束并重、奖罚对等、按绩取酬。 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为进一步完善四川科伦药业股份有限公司（以下简称"公司"）的 治理结构，建立合理有效的企业激励约束机制，提升经营管理效益，根据《中华 人民共和国公司法》《上市公司治理准则》《上市公司章程指引》《深圳证券 交易所股票上市规则》等有关法律、行政法规、部门规章、规范性文件及《四 川科伦药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结 合公司实际情况，制定本制度。 第二章 管理机构 第四条 公司董事、高级管理人员薪酬方案由董事会薪酬与考核委员会制定， 明确薪酬确定依据和具体构成。 董事薪酬方案由股东会审议通过，并予以披露。在董事会或者薪酬与考核委 员会对董事个人进行评价或者讨论其报酬时，该董事应当回避。 高级管理人员薪酬方案由董 ...